Chemotherapy for cholangiocarcinoma

MA Li-wen
DOI: https://doi.org/10.3969/j.issn.1009-0460.2009.09.020
2009-01-01
Chinese Clinical Oncology
Abstract:Cholangiocarcinoma is a rare malignancy associated with poor prognosis and high mortality.Surgical resection is the only chance for cure depending on careful patient selection.There are no well-conducted studies regarding the role of adjuvant chemotherapy.Preliminary data suggests that liver transplantation could offer long-term survival in selected patients when combined with neoadjuvant chemoradiotherapy.In patients with locally advanced or metastatic disease,most studies are small,non-randomized phase Ⅱ trials,and many studies comprise a mix of bile duct cancers,gallbladder cancer,and either pancreatic or hepatocellular cancers.In advanced cancer,phase Ⅱ studies with several cytotoxics,including gemcitabine,the platinums,and the fluoropyrimidines,have shown a modest and often short-lasting activity.No single chemotherapy agent or combination regimen can therefore be recommended as a standard of care at present.
What problem does this paper attempt to address?